The SME initial public offering (IPO) of Vijayawada-headquartered multi-specialty diagnostic and imaging services provider Pramodini Medicare Limited opened for public bidding across the bourses today, Wednesday, August 12, 2026.
Carrying an aggregate issue size of ₹69.04 crore set within an official price band parameter of ₹110.00 to ₹118.00 per share, the public offer marks a major capital market launch for the Andhra Pradesh-based healthcare diagnostic major.
By the close of its opening bidding session across the NSE SME platform at 5:00 PM IST, central exchange engines logged overall valid electronic application tokens for 31,27,200 shares against a net public offer pool of 41,54,400 shares (excluding anchor allocations and the market maker quota). This places the issue at a steady opening Day 1 subscription baseline of 0.75 times (75% coverage).
Qualified Institutional Buyers (QIBs) spearheaded the opening day volume push by taking their reserved quota past full baseline coverage to 1.81 times, while retail and wealth categories registered early opening application entries.
The multi-day public bidding window will remain open through Friday, August 14, 2026.
Here is an extended, plain-English human breakdown covering opening day subscription metrics, unlisted grey market trends, business operations across radiology and pathology, financial health, diagnostic equipment expansion plans, valuation parameters, and the allotment schedule.
1. Day 1 Subscription Data Breakdown
By 5:00 PM on Day 1, central processing engines recorded valid electronic matching tokens worth ₹36.90 crore (calculated at the upper price band cap of ₹118 per share), covering 75% of the net public offer.
The table below summarizes the opening session's performance across investor categories:
+-----------------------------------------------------------------------------------+ | PRAMODINI MEDICARE LIMITED: DAY 1 SUBSCRIPTION DATA | +-------------------+-----------------+------------------+------------------+-------+ | Category | Shares Offered | Shares Bid For | Subscription (x) | Value | +-------------------+-----------------+------------------+------------------+-------+ | QIB (Institutions)| 11,71,200 | 21,18,000 | 1.81x | ₹24.99Cr | NII / HNI (Wealth)| 9,60,000 | 2,17,200 | 0.23x | ₹2.56Cr | Retail (RII) | 20,23,200 | 7,92,000 | 0.39x | ₹9.35Cr | Market Maker | 3,36,000 | — | — | — | +-------------------+-----------------+------------------+------------------+-------+ | Total Net Offer | 41,54,400 | 31,27,200 | 0.75x | ₹36.90Cr +-------------------+-----------------+------------------+------------------+-------+
Analyzing the Category Inflows:
- Qualified Institutional Buyers (QIB - 1.81x): Institutional buyers took the lead on Day 1, submitting bids for 21.18 lakh shares against 11.71 lakh shares reserved for them (excluding anchor allocations), driving the QIB category past full coverage to 1.81 times (totaling ₹24.99 crore).
- Retail Individual Investors (RII - 0.39x): Everyday retail accounts submitted electronic bids for 7.92 lakh shares (330 application lots) against 20.23 lakh shares allocated to their tranche, achieving 39% coverage (totaling ₹9.35 crore). Under the issue rules, retail applicants face a minimum lot requirement of 2 lots (2,400 shares), requiring an upfront application layout of ₹2,83,200 at ₹118 per share.
- Non-Institutional Investors (NII / HNI - 0.23x): High-net-worth wealth accounts filed bids for 2.17 lakh shares on Day 1, reaching 23% coverage (totaling ₹2.56 crore). SME offerings carrying higher retail entry tickets (₹2.83 lakh minimum) traditionally see the bulk of their HNI bidding volume concentration develop on the final afternoon session.
- Anchor Investor Placement: Prior to the public open, Pramodini Medicare successfully placed 13.60 lakh shares with institutional anchor investors on Tuesday, August 11, 2026, raising ₹16.06 crore at ₹118 per share.
- Market Maker Block: A dedicated block of 3,36,000 shares (~₹3.96 crore) is allocated to the designated market makers (Shreni Shares & Rainbow Securities) to provide secondary market liquidity support post-listing.
2. Unlisted Grey Market Premium (GMP) & Market Sentiment
In the unofficial grey market, sentiment surrounding Pramodini Medicare is currently neutral as the issue opens:
- Issue Price Band: ₹110.00 to ₹118.00 per share
- Current Grey Market Premium (GMP): Tracking around +₹0.00 per share (Trading Flat)
- Estimated Listing Price Range: Expected debut counter level of ₹118.00 per share
- Projected Listing Gain Margin: 0.00%
- Retail Application Lot Size: 2 Lots / 2,400 Shares (Minimum Investment: ₹2,83,200)
(Note: Grey market premiums represent informal, off-exchange quotes. They fluctuate based on daily market sentiment and broad equity benchmark trends, and should not be taken as a guaranteed listing return.)
3. Business Overview: What Does Pramodini Medicare Do?
Incorporated in September 2000 and headquartered in Vijayawada, Andhra Pradesh, Pramodini Medicare Limited is a multi-specialty diagnostic, imaging, and clinical pathology services provider.
Starting as a standalone diagnostic center, the company has evolved into a technology-enabled, multi-state diagnostic services platform operating across radiology, advanced nuclear medicine, and automated clinical pathology across Tier-1, Tier-2, and Tier-3 cities in South India.
+-----------------------------------------------------------------------------------+ | PRAMODINI MEDICARE BUSINESS AT A GLANCE | +-----------------------------------+-----------------------------------------------+ | Core Focus Area | Integrated Medical Diagnostics & Imaging | | | (Radiology, PET-CT, MRI, Pathology Labs) | +-----------------------------------+-----------------------------------------------+ | Diagnostic Modality Portfolio | MRI, CT Scans, PET-CT, SPECT, Mammography, | | | Ultrasound, DEXA, X-Ray & Full Pathology Tests| +-----------------------------------+-----------------------------------------------+ | Operating Business Model | Public-Private Partnerships (PPP), Hospital | | | Strategic Alliances & Standalone Centers | +-----------------------------------+-----------------------------------------------+ | Primary Geographic Footprint | Andhra Pradesh, Telangana & South India | +-----------------------------------+-----------------------------------------------+ | Head Office | Vijayawada, Andhra Pradesh | +-----------------------------------+-----------------------------------------------+
Core Competitive Moats:
1. Comprehensive Advanced Modality Infrastructure
Unlike basic blood testing collection booths, Pramodini Medicare operates high-end imaging modalities—including high-field MRI scanners, multi-slice CT machines, PET-CT scanners for oncology diagnostics, and SPECT nuclear medicine systems. Offering radiology and pathology under one roof creates high doctor referral loyalty and multi-test ticket sizes.
2. Hybrid Asset-Light Partnership Model
The company expands its reach through Public-Private Partnerships (PPP) with state health departments, hospital-based diagnostic arrangements, and strategic alliances with medical colleges and public sector undertakings (PSUs). Operating diagnostic hubs inside existing hospitals lowers real estate capex and provides immediate patient traffic.
3. Centralized Tele-Radiology & Pathology Reporting
By linking regional imaging scanners to a centralized tele-radiology network, senior radiologists and pathologists in Vijayawada can analyze scans remotely in real-time, allowing Pramodini to offer specialized reporting standards in smaller Tier-2 and Tier-3 towns without needing full-time senior specialists stationed at every remote site.
4. Detailed Financial Performance (FY24 to FY26)
An audit of the company's restated consolidated financial statements shows rapid top-line scaling along with exceptional EBITDA and net profit margins over the last three fiscal years.
+-----------------------------------------------------------------------------------+ | PRAMODINI MEDICARE: 3-YEAR FINANCIAL PERFORMANCE | +-------------------------------+-------------------+-------------------+-----------+ | Financial Metric (₹ in Cr) | FY24 | FY25 | FY26 | +-------------------------------+-------------------+-------------------+-----------+ | Total Revenue / Income | 35.79 | 38.55 | 63.38 | | EBITDA | 15.53 | 20.97 | 30.90 | | EBITDA Margin (%) | 44.09% | 54.83% | 49.61% | | Net Profit After Tax (PAT) | 7.14 | 11.14 | 17.38 | | PAT Margin (%) | 16.35% | 26.26% | 27.90% | | Total Assets | 48.78 | 56.45 | 93.62 | | Total Debt / Borrowings | 11.96 | 10.81 | 17.85 | | Net Worth | 24.75 | 35.77 | 53.15 | | Return on Net Worth (RoNW %) | 25.54% | 30.81% | 32.69% | +-------------------------------+-------------------+-------------------+-----------+
Key Financial Observations:
- Fast Top-Line Scaling: Total income expanded from ₹35.79 crore in FY24 to ₹38.55 crore in FY25, before surging 64.4% YoY to ₹63.38 crore in FY26. This revenue growth was driven by higher diagnostic patient volumes across radiology and PET-CT oncology imaging.
- Elite Operational Profitability: Operating EBITDA margins reached 49.61% in FY26 (EBITDA of ₹30.90 crore), while net profit after tax (PAT) jumped 56% YoY from ₹11.14 crore in FY25 to ₹17.38 crore in FY26 (PAT margin of 27.90%). Diagnostic imaging assets carry high gross operating leverage once fixed machine lease costs are covered.
- High Return Ratios: The company operates with high internal capital efficiency, delivering a Return on Equity / RoNW of 32.69% and a Return on Capital Employed (ROCE) of 34.66% in FY26.
5. Structure of the Offer & Objects of the Issue
The ₹69.04 crore public issue is split into fresh capital and an offer for sale:
+-----------------------------------------------------------------------------------+ | IPO CAPITAL STRUCTURE BREAKDOWN | +-----------------------------------+-----------------------------------------------+ | Total Issue Size | ₹69.04 Crore (58,51,200 Equity Shares) | +-----------------------------------+-----------------------------------------------+ | Fresh Issue Component | ₹63.14 Crore (53,50,800 Equity Shares) | +-----------------------------------+-----------------------------------------------+ | Offer for Sale (OFS) Component | ₹5.90 Crore (5,00,400 Equity Shares) | +-----------------------------------+-----------------------------------------------+ | Price Band | ₹110 to ₹118 per share | +-----------------------------------+-----------------------------------------------+ | Face Value | ₹10 per share | +-----------------------------------+-----------------------------------------------+ | Market Maker Block | 3,36,000 Shares (₹3.96 Crore Value) | +-----------------------------------+-----------------------------------------------+ | Lead Manager (BRLM) | Smart Horizon Capital Advisors Private Ltd | +-----------------------------------+-----------------------------------------------+ | Registrar to the Issue | Purva Sharegistry (India) Private Limited | +-----------------------------------+-----------------------------------------------+
How Will Fresh Issue Capital Be Deployed?
Out of the ₹69.04 crore total issue size, ₹63.14 crore represents fresh primary capital coming directly onto the company balance sheet. Pramodini Medicare will deploy these proceeds into two primary areas:
- CAPEX for Advanced Medical Equipment Purchase (₹45.15 Crore / 71.5%): Directed to acquire advanced MRI scanners, CT machines, PET-CT systems, and automated pathology analyzers to upgrade existing centers and outfit proposed diagnostic centers in Andhra Pradesh and Telangana.
- General Corporate Purposes & Strategic Acquisitions (₹17.99 Crore / 28.5%): Allocated to support administrative run-rates, brand building, and explore inorganic acquisitions of smaller regional diagnostic labs.
Understanding the Offer for Sale (OFS):
The remaining ₹5.90 crore is an Offer for Sale (OFS) of 5,00,400 shares by promoter selling shareholders. OFS proceeds go directly to the selling shareholders.
6. Valuation Analysis & Peer Group Comparison
At the upper price band cap of ₹118 per share, Pramodini Medicare is priced at a trailing Price-to-Earnings (P/E) multiple of 11.34x based on its pre-issue FY26 basic EPS of ₹10.41 (and 14.97x based on post-issue diluted EPS of ₹7.88), establishing a post-issue corporate market capitalization of approximately ₹260.14 crore.
Let's compare this with listed diagnostic and healthcare services peers in India:
+-----------------------------------------------------------------------------------+ | PEER GROUP VALUATION COMPARISON | +-----------------------------------+--------------------+--------------------------+ | Company Name | Trailing P/E (x) | Primary Focus / Model | +-----------------------------------+--------------------+--------------------------+ | Pramodini Medicare (At ₹118) | ~14.97x (Post-IPO) | Diagnostic & Imaging | | Dr. Lal PathLabs Ltd | ~62.10x | Pathology Lab Network | | Metropolis Healthcare Ltd | ~54.30x | Diagnostic Testing Chain | | Krsnaa Diagnostics Ltd | ~36.50x | PPP Diagnostic Major | | Vijaya Diagnostic Centre Ltd | ~52.80x | South India Imaging Hub | +-----------------------------------+--------------------+--------------------------+
Valuation Summary:
At 14.97x post-issue FY26 trailing earnings, Pramodini Medicare enters the exchange portals at an attractive, value-oriented valuation structure compared to listed PPP diagnostic major Krsnaa Diagnostics (~36.5x P/E) and South Indian diagnostic leader Vijaya Diagnostic (~52.8x P/E).
Given its ₹63.38 crore revenue scale, 49.61% EBITDA margins, 32.69% RoNW returns, and PAT reaching ₹17.38 crore, the ~15.0x post-issue P/E multiple leaves a healthy fundamental margin of safety for incoming public investors.
7. Core Strengths vs. Key Business Risks
Investors evaluating this SME healthcare issue should consider the following operational factors:
Key Strengths:
- Disciplined Valuation (14.97x Post-IPO P/E): Priced at ~15.0x post-issue earnings, offering a significant valuation discount compared to listed diagnostic peers.
- 1.81x QIB Day 1 Coverage: QIB quota fully subscribed on opening day, showing solid early institutional confidence.
- Outstanding Operating Margins: Delivering a 49.61% EBITDA margin and a 27.90% PAT margin in FY26.
- Strong Return Ratios: Return on Net Worth (RoNW) standing at 32.69% alongside ROCE at 34.66%.
Key Risk Factors:
- Geographic Concentration Risk: A substantial portion of annual operating revenue originates from diagnostic centers in Andhra Pradesh and Telangana, leaving operations sensitive to regional regulatory or healthcare policy shifts.
- Medical Equipment Obsolescence: Radiology and nuclear medicine equipment require ongoing capital expenditure for technology upgrades and maintenance contracts.
- High Retail Application Threshold: The minimum investment required for retail applicants is ₹2,83,200 (2 lots / 2,400 shares), which restricts participation from smaller retail accounts.
8. Application Matrix & Key Timeline
If you are planning to apply for the Pramodini Medicare IPO, here is the upcoming schedule and application size breakdown:
- Public Bidding Window Opens: Wednesday, August 12, 2026 (Status: Live / Day 1 Complete)
- Public Bidding Window Closes: Friday, August 14, 2026 (5:00 PM IST)
- Basis of Allotment Finalization: Monday, August 17, 2026
- Refund Initiations & Unblocking of Bank Funds: Tuesday, August 18, 2026
- Credit of Equity Shares to Demat Accounts: Tuesday, August 18, 2026
- Official Stock Exchange Listing (NSE SME): Wednesday, August 19, 2026
- Designated Registrar: Purva Sharegistry (India) Private Limited
Application Size Matrix:
- Retail Minimum & Maximum: 2 Lots (2,400 Shares) — ₹2,83,200
- Small HNI (sNII) Minimum: 3 Lots (3,600 Shares) — ₹4,24,800
- Big HNI (bNII) Minimum: 8 Lots (9,600 Shares) — ₹11,32,800
Conclusion: What Should You Watch for on Day 2 & Day 3?
Pramodini Medicare presents a compelling healthcare diagnostic growth story backed by a 64% YoY top-line jump to ₹63.38 crore, 49.6% EBITDA margins, 32.7% RoNW returns, and an attractive 14.97x post-issue trailing P/E multiple.
With Day 1 subscription closing at 0.75x overall (supported by 1.81x QIB coverage), watch how retail and wealth categories build up their order blocks over the next two days ahead of Friday's closing deadline.
Post Excerpt
A complete Day 1 analysis of the ₹69.04 crore Pramodini Medicare SME IPO. Bids opened at 0.75x baseline on Day 1 with QIBs subscribed at 1.81x. Read our full review of company financials, PET-CT radiology and pathology moats, grey market trends, equipment capex plans, valuation (14.97x post-issue P/E), and timeline ahead of the August 14 close.